BeiGene (BGNE US) – Three Synergistic Haematology BIC/FIC Molecules Showing Promising Data
⬆ $BeiGene (BGNE)$ - Additional studies presented at ASH indicated that zanu provided meaningful benefits for acalabrutinib-intolerant patients, which could lead to zanu’s global market share gain, in our view.
Continue reading on Smartkarma:- https://www.smartkarma.com/insights/beigene-bgne-us-three-synergistic-haematology-bic-fic-molecules-showing-promising-data?utm_source=tiger_community
By CMB International, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/cmb-international?utm_source=tiger_community
On BeiGene (BGNE):- https://www.smartkarma.com/entities/beigene-ltd-b5b6d079-eb7e-41a8-9ac4-a391831e02f4?utm_source=tiger_community
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
